The mammary ducts of humans and mice are comprised of two main mammary epithelial cell (MEC) subtypes: a surrounding layer of basal MECs and an inner layer of luminal MECs. Breast cancer subtypes show divergent clinical behavior that may reflect properties inherent in their MEC compartment of origin. How the response to a cancer-initiating genetic event is shaped by MEC subtype remains largely unexplored. Using the mouse mammary gland, we designed organotypic three-dimensional culture models that permit challenge of discrete MEC compartments with the same oncogenic insult. Mammary organoids were prepared from mice engineered for compartment-restricted coexpression of oncogenic H-RAS G12V together with a nuclear fluorescent reporter. 
Introduction
Mammary epithelium is comprised of 2 concentric cell compartments that are functionally distinct. The inner luminal mammary epithelial cell (MEC) layer harbors cells responsible for milk production, whereas the outer basal mammary epithelial cell (MEC) layer forms a sheath of myoepithelial cells whose contractility enables milk delivery (1) . The ontogeny of these compartments remains incompletely defined. Landmark studies showed that a small subset of basal-like MECs can give rise to all MEC subtypes in mammary gland reconstitution assays, suggesting a precursor-product relationship between basal and luminal MECs (2, 3) . However, recent lineage tracing studies show that the basal and luminal MEC lineages diverge during embryonic development, after which MECs remain lineage-confined throughout postnatal mammary development (4) . Thus, the bulk of mammary gland growth, development, and maintenance likely depends on compartmentrestricted MECs.
Distinct breast cancer subtypes have been proposed to arise from malignant transformation of distinct MEC subtypes. It follows that the divergent clinical behavior of breast cancer subtypes may be attributable in part to epigenetic traits inherited from diverse cells of origin (5) . Intriguingly, distinct MEC subsets can yield biologically distinct cancers under some experimental conditions (6, 7) . How the biology of MEC subtypes shapes the clinical behavior of descendant mammary cancers remains elusive due to the complexity inherent in multistep tumor progression. Recent reports caution against assuming that breast cancers faithfully maintain biologic features of their cells of origin. For example, both human and mouse studies suggest that basal-type breast cancers may arise from a luminal progenitor MEC population (8, 9) , indicating that clonal evolution can obscure lineage history.
Since clonal evolution confounds efforts to uncover MEC subtype-specific mechanisms of transformation, we sought a strategy that would allow discrete MEC compartments to be challenged with a single initiating oncogenic lesion, then monitored prospectively during the initiation of neoplastic growth. Mammary organoids placed in 3-dimensional (3D) culture under defined media conditions retain the bilayered architecture of the native mammary gland and remain competent to recapitulate complex developmental programs ex vivo when stimulated with growth factors (10) . Adding transgene-encoded fluorescent reporters renders these organoids amenable to time-lapse imaging at single-cell resolution (11) . Illustrating the power of this methodology, live MEC monitoring during organoid branching morphogenesis revealed a novel mode of cell migration and invasion termed multilayered epithelial elongation (11) . Whether this physiologic mode of invasion is coopted by oncogenes to render MECs invasive remains unknown.
To elucidate early steps in the transformation of discrete MEC subsets, we generated mice harboring transgene combinations designed to permit MEC compartment-restricted expression of inducible oncogenes in organoid culture. As a test case, we chose to examine the impact of challenging discrete MEC compartments with the same oncogenic H-RAS G12V allele. Though mutations in H-RAS or the closely related K-RAS and N-RAS genes are rare in primary human breast cancers, they are common in established breast cancer cell lines (12) and frequently arise as cooperating lesions in mouse breast cancer models (13) (14) (15) . More importantly, a large fraction of breast cancers harbor mutations that activate signaling pathways linked to Ras. HER2/neu-dependent signaling lies upstream of Ras and provides a validated drug target in more than 20% of breast cancers (16) . In addition, roughly 30% of breast cancers harbor PIK3CA mutations that activate a key effector pathway downstream of Ras (17) .
Materials and Methods

Transgenic mice
Mice were housed in a barrier facility with access to water and chow (Harlan Tekland, HT2018) ad libitum. All experimental protocols were approved by the Penn State College of Medicine Institutional Animal Care and Use Committee Committee. Transgenic mouse strains used were as follows: tetO-H2B-eGFP (Jackson Labs), MMTV-rtTA (gift from Lewis Chodosh, University of Pennsylvania, Philadelphia, PA), K5-rtTA (Adam Glick, Pennsylvania State University, University Park, PA), FVB-Tg(tetO-HRAS)65Lc (NCI Mouse Repository). Mice were genotyped by performing PCR on tail clip-derived genomic DNA. PCR primers are available on request. Both Keratin-5-rtTA/TRAS/TGFP and MMTV-rtTA/TRAS/TGFP tritransgenic mice remained healthy while Dox-na€ ve, but became ill within 24 to 48 hours of Dox treatment. This TRAS transgene-associated morbidity precluded study of Ras-mediated phenotypes in vivo.
Mammary organoid preparation and culture
Organoids were generated from mammary tissue using mechanical dissociation and enzymatic digestion, followed by filtration and differential centrifugation steps as described (10, 11) . Pelleted organoids were resuspended in Growth Factor Reduced Matrigel (GFR Matrigel, BD Biosciences) for plating. Wells of an optical-grade 96-well plate were precoated with 10 uL of GFR Matrigel underlay and permitted to set for 20 minutes at 37 C. A 45 mL suspension of organoids plus GFR-Matrigel was placed atop the underlay and permitted to set for 30 minutes at 37 C before overlaying 200 mL of organoid culture media. Doxfree organoid culture media consisted of the following: Dulbecco's Modified Eagle's Media/F12 plus Â2 antibiotic/antimycotic plus ITS (10 mg/mL insulin, 5.5 mg/mL transferrin, and 2 ng/mL sodium selenite, all from Sigma). Organoid culture plates were typically allowed to equilibrate for 24 hours in a 37 C incubator before initiating experiments and acquiring images. Culture media was changed every other day. Media additives and growth factors at their typical final concentrations were as follows: Dox (Sigma, 1,000 ng/mL); fibroblastic growth factor, basic (Sigma, 50 ng/mL in TRIS, pH ¼ 7.0); PD0325901 [Cayman Chemicals, 100 nmol/L in dimethyl sulfoxide (DMSO); LY294002 Calbiochem, 10 umol/L, in DMSO]; Rapamycin (Rap; gift from Leonard Jefferson, Penn State College of Medicine, 5 nmol/L in ethanol). In experiments using inhibitors, inhibitor-free control wells were administered equivalent doses of DMSO or ethanol carrier. Organoid recovery for confocal microscopy was performed at room temperature as described (10) , and slides were stored at À20 C until analysis.
Microscopy
Time-lapse imaging was performed using a Zeiss Axiovision Observer microscope with a Â20 objective lens and an AxioCam MRM camera. Temperature was held at 37 C and CO 2 concentration at 5% using a Zeiss Temp Module S, CO 2 Module S, and Heating Unit XL. Images of each organoid were acquired every 15 minutes using a robotic stage and Axiovision Multidimensional Imaging Modules, with Time-Lapse and Mark and Find functions. Time-lapse images were collected for up to 7 days, with images acquired and saved in 12 to 24 hour blocks. After each daily acquisition period, the z-axis was reset to maximize image focus.
For confocal microscopy, z-stacks were acquired using a Leica TCS SP2 AOBS inverted stage confocal microscope with laser lines 405, 476, and 543 (to detect nuclear GFP, Hoechst, and rhodamine phalloidin, respectively). Images were captured using either a Â40 or a Â63 objective lens.
Image and statistical analysis
To determine changes in organoid size and morphology, wide-field microscopy images were measured for 2-dimensional (2D) area and circularity. For area measurements, 2D organoid borders were traced. Area and perimeter measurements were determined using Zeiss Axiovision software. Circularity is a unitless measurement of the compactness of a shape, and ranges from 0 to 1. A perfect circle results in a circularity of 1. Using perimeter and area measurements, circularity was measured using the formula: 4p(area)/(perimeter) 2 . Statistical significance on these measurements was determined by using ANOVA or repeated measures ANOVA analysis, where applicable. Individual group differences were then determined using the Tukey-Kramer Procedure. Repeated measures ANOVAs were used when organoid area or circularity was measured over time.
Mitotic and cell death events were quantified by tallying events observed during frame-by-frame analysis of time-lapse image sequences acquired between 24 and 72 hours of Dox treatment. For statistical analysis, ANOVA analysis was performed, followed by the Tukey-Kramer Procedure for individual group differences. When only the difference between 2 groups was important, 2-tailed Student t tests were performed.
Results
First, we tested transgene combinations designed to restrict expression of identical tet-regulated responder genes to distinct MEC compartments. For luminal-restricted expression, a previously characterized MMTV-rtTA transactivator line was used (18) . For basal-restricted expression, we tested a Keratin-5-rtTA (K5-rtTA) transactivator line (19) . Each transactivator line was crossed to a tet-O-H2BGFP (hereafter TGFP) reporter line (20) and bitransgenic K5-rtTA/TGFP (basal GFP ) and MMTV-rtTA/TGFP (luminal GFP ) offspring were identified. Then, mammary organoids were prepared from Dox-na€ ve females, placed in 3D Matrigel culture, and subjected to live cell imaging before and after Dox addition.
Both basal GFP and luminal GFP organoids consistently lacked detectable GFP fluorescence in the absence of Dox treatment when visualized by wide-field fluorescent microscopy. Within 24 hours of Dox treatment, organoids of both genotypes showed robust labeling with numerous H2BGFP-positive cells ( Fig. 1A ; Videos 1 and 2). Most H2BGFP-labeled MECs resided near the periphery of basal GFP organoids, but near the center of luminal GFP organoids (Fig. 1A) , consistent with transactivatorspecific labeling of spatially distinct MEC subsets. Similarly, these transgene combinations enable Dox-dependent labeling of spatially distinct MEC compartments in vivo (Mathers J.M. and Gunther E.J., unpublished data). To better define the cell compartments labeled by each transactivator in vitro, organoids collected at the conclusion of live cell imaging were counterstained and visualized by confocal microscopy (Fig.   1B ). Optical sections through basal GFP organoids revealed H2BGFP-labeled cells exclusively in the outermost basal MEC layer. By contrast, luminal GFP organoids never contained labeled cells within this outer layer; instead, labeled cells exclusively resided internally. Labeling was highly compartment restricted but incomplete in that each transactivator labeled only a subset of the cells in its respective compartment. When basal GFP and luminal GFP organoids were subjected to extended live cell imaging with image capture every 15 minutes, nuclear H2BGFP fluorescence typically permitted tracking of individual MECs over many hours of imaging (Videos 1 and 2). Moreover, frame-by-frame analysis of time-lapse videos routinely permitted visualization of MEC mitoses and cell death events (Fig. 1C) .
To challenge discrete MEC compartments with the same oncogenic insult, crosses were performed to introduce a tet- ) tritransgenic mice. Mammary glands derived from Dox-na€ ve transgenic mice showed normal histomorphology, and sections from transgenic mammary glands showed normal MEC compartmentalization when subjected to immunohistochemistry using basal and luminal MEC markers ( Fig. 2A) . Organoids prepared from these glands were cultured in 3D and subjected to live cell imaging as before. In the absence of Dox treatment, basal RAS/GFP and luminal RAS/GFP organoids lacked detectable H2BGFP label and were morphologically indistinguishable from wild-type organoids, indicating tight regulation of the responder transgenes. In contrast, Dox treatment of both basal RAS/GFP and luminal RAS/GFP organoids triggered markedly aberrant organoid overgrowth ( Fig. 2B ; Videos 3 and 4). Genetic control organoids lacking the TRAS transgene (derived from basal GFP and luminal GFP mice) cultured in neighboring wells underwent Dox-dependent H2BGFP labeling but lacked Rasmediated perturbations in organoid morphology and size, showing that Dox treatment on its own did not perturb growth.
To quantify Ras-mediated changes in organoid size and morphology, wide-field microscopy images of individual organoids were acquired after 1 week of culture and subjected to software-based image analysis. Organoid size was quantified by measuring organoid area in 2D. Organoid morphology was quantified by using 2D measurements to calculate circularity values indicative of organoid "roundness" (derived circularity values approach one as objects more closely approximate a perfect circle but decline as objects become less round, see Materials and Methods). Size and circularity measurements for representative sets of organoids were then compared across genotypes and Dox treatment conditions.
For both basal RAS/GFP and luminal RAS/GFP organoids, Dox treatment reproducibly increased size and decreased circularity in comparison to genetic and Dox-na€ ve controls (Fig. 2C) . Changes occurring in luminal RAS/GFP organoids (9-fold increase in size vs. controls; 0.46 decrease in circularity) were modestly more pronounced than those occurring in basal RAS/GFP organoids (6-fold increase in size; 0.31 decrease in circularity). These differences may be attributable in part to the luminal transactivator targeting a larger MEC population at the outset (Fig. 1B) .
To examine the cellular mechanisms of Ras-mediated overgrowth, live cell imaging videos from the first 72 hours of Dox treatment were viewed frame-by-frame to identify MEC mitoses and cell death events. Ras expression in either compartment markedly increased the number of cell divisions and decreased the number of cell death events. Compared against GFP-only genetic controls, mitoses in basal RAS/GFP and luminal RAS/GFP organoids were elevated 20-fold and 11-fold, respectively, whereas cell death events decreased approximately 4-fold and 3-fold, respectively (Fig. 2D) . These findings are consistent with Ras imparting both proproliferative and prosurvival signals in a cell autonomous manner, whether expressed basally or luminally.
Next, Ras-driven perturbations in morphogenesis were compared with a well-defined morphogenesis program triggered by growth factor supplementation. Organoids stimulated with Fgf2 use a mode of collective cell migration termed multilayered epithelial elongation when completing a morphogenesis program closely akin to physiologic mammary branching (11) .
We confirmed that Fgf2-induced multilayered epithelial elongation proceeds without basally directed MEC extensions and protrusions and absent solitary "leader" cells at the forefront of invasion (Fig. 3A) . Moreover, MECs at sites of Fgf2-induced branching aligned to form a smooth multicellular border at the invasion front. By contrast, for both basal RAS/GFP and luminal RAS/GFP organoids, Ras activation triggered focal invasion initiated by solitary leader cells, which typically extended 1 or more basal cellular protrusions into the surrounding Matrigel (Fig. 3B) . Neighboring MECs migrated behind these leader cells, forming solid strands of invading cells. Typically, leader cells emerged at multiple sites along the organoid periphery, initiating numerous invasion foci and generating an irregular organoid border. This mode of invasion was clearly Ras initiated, as nearly all basal RAS/GFP and luminal RAS/GFP organoids developed invasive foci during Dox treatment, whereas both Dox-na€ ve and genetic control organoids almost never did (Fig. 3C) . To contrast the growth factor-driven and Ras-driven modes of collective cell migration within the same organoid, luminal RAS/GFP organoids were first stimulated with Fgf2 under Dox-free conditions for 1 week, permitting branching morphogenesis. Upon subsequent Dox addition, Ras activation triggered the formation of multiple invasive foci on each organoid, with basal cellular protrusions and migrating leader cells evident within 24 hours (Fig. 3D) .
To determine the downstream signaling pathways engaged during Ras-mediated MEC overgrowth, pharmacologic inhibitors of well-known Ras effector pathways were employed at standard doses in time-lapse imaging experiments. Blockade of the mitogen-activated protein kinase (MAPK) cascade using the MAP-ERK kinase (MEK) inhibitor PD0325901 (PD) only modestly suppressed Ras-driven phenotypes in both MEC compartments ( Fig. 4 ; Videos 5 and 6). Notably, for both basal RAS/GFP and luminal RAS/GFP organoids, Dox-dependent initiation of focal invasion was unimpeded by PD, and gross organoid morphology as quantified by circularity measurements was only partially preserved. Likewise, PD only partially suppressed overgrowth of both basal RAS/GFP and luminal RAS/GFP organoids, in each case reducing Ras-mediated increases in organoid size approximately 2-fold. While these findings indicate that MAPK pathway activation contributes to Ras-mediated phenotypes in both MEC compartments, they underscore likely roles for additional Ras effectors in the invasion and overgrowth of both basal and luminal MECs.
Whereas both basal RAS/GFP and luminal RAS/GFP organoids responded similarly to MAPK pathway inhibition, outcomes for each compartment following phosphoinositide 3-kinase (PI3K) inhibition with LY294002 (LY) were strikingly divergent ( Fig. 5A; Videos 7 and 8) . For luminal RAS/GFP organoids, LY failed to suppress Ras-initiated focal invasion or preserve circularity, and partially suppressed organoid overgrowth by reducing Ras-mediated increases in organoid size approximately 2-fold. In contrast, for basal RAS/GFP organoids, LY completely suppressed all Ras-mediated phenotypes initiated by Dox induction (Fig. 5A) . Indeed, basal RAS/GFP organoids treated with both Dox and LY were, by morphometry, indistinguishable from Dox-na€ ve controls. Notably, despite abrogating Ras-mediated overgrowth, LY treatment of Doxinduced basal RAS/GFP organoids did not prevent H2BGFP labeling of basal MECs (Fig. 5A, lower left) , showing that LY does not act by inhibiting Dox-induced transgene expression. To confirm and extend these findings, Rap was used to inhibit mTOR, a known downstream effector of PI3K pathway activation (Fig. 5B) . Strikingly, Rap treatment provided a close phenocopy of LY treatment. Like LY, Rap completely suppressed all Ras-mediated phenotypes in basal RAS/GFP organoids, including overgrowth, without precluding the H2BGFP labeling indicative of transgene induction ( Fig. 5B ; Videos 9 and 10). Taken together, the LY and Rap treatment outcomes show that basal MECs, unlike their luminal counterparts, strictly depend on PI3K/mTOR signaling during Ras-mediated invasive overgrowth.
To examine the cellular mechanisms whereby inhibitors suppress Ras-mediated overgrowth, we again scored live cell imaging videos from the first 72 hours of Dox treatment to quantify MEC fates. For both basal RAS/GFP and luminal RAS/GFP organoids, MEK inhibition with PD yielded no discernible changes in the frequency of mitoses and cell death events (Fig. 6A ), in keeping with the relatively modest impact of PD on organoid morphology and size. In contrast, inhibition of PI3K/ mTOR signaling by either LY or Rap treatment altered MEC fates in a compartment-specific manner (Fig. 6B) . Whereas the frequency of mitotic events for luminal RAS/GFP organoids was unchanged by LY and reduced only modestly by Rap (38% reduction), mitoses in basal RAS/GFP organoids were reduced 3-fold by each inhibitor (Fig. 6B, left) . Neither LY nor Rap treatment changed the frequency of cell death events in luminal RAS/GFP organoids. Interestingly, although both LY and Rap completely suppressed Ras-mediated phenotypes in basal RAS/GFP organoids, LY increased the number of MEC death events 8-fold whereas Rap treatment yielded no detectable change (Fig. 6B, right) . Thus, treatments that suppressed invasive overgrowth of basal MECs consistently decreased cell proliferation but variably impacted cell death. These findings suggest that proliferation arrest may be the primary means by which PI3K/mTOR pathway inhibition counters the Ras-mediated overgrowth of basal MECs.
In our inhibitor studies, treatment conditions that robustly suppressed Ras-driven increases in organoid size also preserved gross organoid morphology by preventing focal invasion. As disruptions in cell polarity and tissue architecture promote mammary tumorigenesis (22), we examined whether treatments that abrogate Ras-driven invasion and overgrowth also preserve the organization of MEC compartments. Organoids collected at the conclusion of inhibitor experiments were counterstained and visualized by confocal microscopy (Fig.  6C) . Examination of optical sections from basal RAS/GFP and luminal RAS/GFP organoids after 6 days of Dox treatment in the absence of inhibitors revealed H2BGFP-labeled MECs dispersed throughout both the periphery and center of organoids, indicating Ras-driven loss of MEC compartmentalization. For basal RAS/GFP organoids, when either LY or Rap was coadministered with Dox, PI3K/mTOR inhibition not only blocked overgrowth but also preserved MEC compartments, since H2BGFP-labeled cells continued to reside exclusively in the outermost MEC layer. These findings link Ras-driven organoid overgrowth to a breakdown in MEC compartmentalization.
Next, we considered whether the failure to block Ras-driven overgrowth of luminal MECs with PI3K/mTOR pathway inhibitors might be a trivial consequence of achieving higher levels of Ras pathway activation using our luminal transactivator. To test this possibility, both luminal RAS/GFP and basal RAS/GFP organoids were treated for 7 days with a range Figure 4 . MEK inhibition partially blocks Ras phenotypes in both MEC compartments. Basal RAS/GFP and luminal RAS/GFP organoids were cultured under the indicated treatment conditions for 6 days. PD denotes MEK inhibitor PD0325901 at 100 nmol/L. Left panels depict day 6 images (Â10) of representative organoids for each genotype and treatment condition (see also Videos 5 and 6). Morphometry of 2D images captured at days 0, 2, 4, and 6 were used to determine the prevalence of focal invasion as well as the mean organoid circularity and area at each time point. Each data point reflects the analysis of 37 to 55 organoids. Error bars denote SEM.
of Dox doses designed to drive varying levels of TRAS transgene expression. In pilot experiments, no changes in organoid size or morphology were apparent below a threshold Dox dose of 25 to 50 ng/mL (data not shown). Escalating Dox doses beyond this threshold yielded monotonic increases in organoid size up to 1,000 ng/mL, indicating graded responses to a dynamic range of Ras activation levels (Fig. 7A) . For basal RAS/GFP organoids, LY treatment completely abrogated Ras-mediated size increases over the full range of Ras activation levels tested. By contrast, for luminal RAS/GFP organoids, LY treatment reduced Ras-mediated size increases by a fixed proportion (approximately 2-fold) at each of the 3 Dox treatment doses tested (Fig. 7A) . Notably, LY treatment only partially blocked Ras-mediated overgrowth of luminal RAS/GFP organoids when coadministered with lower Dox doses that yielded submaximal size increases in the absence of inhibitor. Thus, even in the context of submaximal Ras pathway activation, LY only partially suppressed overgrowth of luminal MECs.
Finally, we tested whether higher doses of Pi3k/mTOR pathway inhibitors would suffice to abrogate Ras-driven overgrowth of luminal MECs. Neither a 2.5-fold increase in LY dose (from 10 to 25 ng/mL) nor a 4-fold increase in Rap dose (from 5 to 20 nmol/L) abrogated Ras-driven overgrowth of luminal RAS/GFP organoids (Fig. 7B) . Furthermore, MEC toxicity became apparent in control organoids when LY was dosed at 25 ng/mL (data not shown), indicating that Ras-driven overgrowth of luminal MECs persists even at the maximum tolerated LY dose.
Discussion
Numerous studies have explored how different cell subsets within a tissue respond to long-term challenge with activated Ras alleles. For example, directing expression of H-RAS G12V transgenes to distinct skin compartments yielded models with markedly different rates of tumor onset and progression (23) . Furthermore, some, but not all, skin compartments gave rise to tumors after undergoing cre-mediated activation of a latent KRas G12D allele (24, 25) . Similarly, activation of latent K-Ras alleles in distinct cell compartments within the pancreas drove tumorigenesis with different rates of onset and different requirements for cooperating tissue injury (26) (27) (28) . By comparison, the short-term impact of cell type on Ras-initiated phenotypes remains largely unexplored.
Challenging basal or luminal MECs with the same oncogenic H-RAS G12V allele triggered an MEC invasion program that differed markedly from the growth factor-initiated invasion program previously shown to recapitulate branching morphogenesis in 3D culture (11) . The specific signaling events that lead to focal invasion upon H-RAS G12V expression rather than multilayered epithelial elongation remain unclear. Mammary organoids engage known Ras effectors, including the MAPK pathway, when stimulated with growth factors (10) , raising the possibility that focal invasion involves activating these same pathways to supraphysiologic levels. Alternatively, focal invasion may result from engaging Ras effector pathways in the wrong MECs or at the wrong time. The precise MEC subset that normally responds to fibroblast growth factor stimulation during branching morphogenesis remains undefined and may not be targeted by the transactivators employed in our study. Furthermore, proper initiation of the branching morphogenesis program may depend upon a specific duration of Ras pathway activation, as suggested by others (10) .
Previous studies have examined links between Ras effector pathways and MEC invasion. When an inducible Raf construct was used to activate the MAP kinase cascade selectively, the MCF-10A line of immortalized human MECs acquired only a noninvasive mode of motility (29) , suggesting that invasion requires input from another Ras effector pathway. However, MCF-10A cells engineered to express breast cancer-associated PIK3CA mutations acquired the capacity for growth factorindependent proliferation, but not invasion (30, 31) . Thus, PI3K pathway activation by itself may be necessary but insufficient to confer invasiveness, as others have suggested based on studies performed on epithelial cell monolayers (32) . Our study extends this paradigm in 2 ways. First, we show that the Ras effectors required for invasion and overgrowth differ for distinct MEC compartments. Second, we show that MEC invasion and overgrowth are closely correlated phenotypes. In our inhibitor studies, treatments that suppressed focal MEC invasion and preserved MEC compartment boundaries also robustly suppressed Ras-mediated overgrowth. These findings add to the accumulating evidence that maintaining proper mammary tissue architecture potently suppresses neoplasia. Why do basal MECs uniquely require PI3K/mTOR signaling for Ras-mediated invasion and overgrowth? The answer may lie in the distinct microenvironments encountered by basal and luminal MECs. Unlike their luminal counterparts, basal MECs reside in direct contact with the extracellular matrix. Recent studies suggest that matrix attachment provides MCF-10A cells with critical cues that promote nutrient uptake and survival (33) . For basal MECs, Ras-driven activation of PI3K/ mTOR signaling may substitute for growth signals lost upon matrix detachment, thereby enabling aberrant compartment egress and expansion. Ras-mediated invasion of basal MECs may involve cell nonautonomous mechanisms as well. H-RAS G12V has been shown to render epithelial cells invasive only when neighboring cells lack mutant Ras, suggesting that invasion can depend on promigratory interactions between mutant and wild-type cells (32) . Our findings do not preclude roles for additional Ras effectors, such as the Ral/GDS pathway, in MEC overgrowth.
Some studies suggest that exogenous mutant Ras alleles yield more extreme phenotypes than corresponding mutations affecting endogenous Ras alleles. Retroviral transduction of
K-Ras
G12V into either MCF-10A cells or human telomerase reverse transcriptase-immortalized human MECs triggered fulminant invasion and overgrowth in 3D culture, whereas clones carrying K-Ras G12V alleles generated by gene targeting showed morphology and growth that were nearly indistinguishable from wild-type (34) . It is unknown whether these discrepancies primarily reflect quantitative or qualitative changes in the signaling events downstream of Ras. Supporting the importance of signaling intensity, strong selective pressure favors increased expression of mutant Ras alleles during the progression of both skin and mammary tumors in mice (35, 36) . Likewise, human tumor cell lines often selectively overexpress endogenous mutant Ras alleles (34) . Therefore, the transgenemediated Ras pathway activation employed in our study may more closely model a scenario in which mutant Ras activity has been augmented by a secondary genetic event, such as copy number gain.
Chronic expression of activated H-RAS alleles in luminal MECs can drive mammary tumorigenesis in transgenic mouse models (35) , whereas the fate of basal MECs similarly challenged remains unknown. Recent studies suggest that basal MECs may infrequently serve as cells-of-origin for highly prevalent breast cancer subtypes. Initiating transformation of luminal MECs from mice (ref. 9; via conditional Brca1 deletion) and from humans (ref. 7; via retroviral transduction) yielded tumors that resembled basal-like ductal carcinomas, a breast cancer subtype commonly encountered in the clinic. By contrast, transformation of basal MECs using identical protocols yielded tumors that resembled extremely rare breast cancer subtypes, namely, adenomyoepitheliomas and metaplastic carcinomas. It will be valuable to confirm these findings using models that permit tracing of MEC lineages in situ during oncogene challenge and tumor progression (5) . Toward this end, we are developing in vivo methods that build upon those described in this report.
Our studies explore signaling dependencies in the immediate aftermath of an initiating oncogenic event. In contrast, mammary tumorigenesis in mice and humans likely requires Figure 7 . PI3k/mTOR blockade abrogates basal but not luminal MEC overgrowth across a range of Ras activation levels and inhibitor doses. Basal RAS/GFP and luminal RAS/GFP organoids were cultured under the indicated treatment conditions for 6 days. 2D image morphometry was used to determine mean organoid area. A, LY effects on organoid size across varied Dox doses. When administered, the LY dose was held constant at 10 mmol/L. B, Inhibitor effects on organoid size across varied drug doses. When administered, the Dox dose was held constant at 1,000 ng/mL. Mean values reflect analysis of 18 to 34 organoids for each genotype and treatment condition. Error bars denote SEM.
the step-wise acquisition of cooperating genetic lesions over months to years. This protracted course leaves ample opportunity for signaling dependencies to change during clonal evolution. However, a recurring theme in molecular oncology is the remarkable degree to which signaling pathway dependencies can remain in force over time, manifesting as oncogene addiction or lineage addiction (37, 38) . We find that, at the initiation stage of MEC transformation, signaling pathway dependencies can be profoundly shaped by MEC subtype. It will be important to determine whether compartment-defined signaling dependencies persist during tumor progression.
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